UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape

Life (Basel, Switzerland), 2024-01, Vol.14 (2), p.198

2024

Volltextzugriff (PDF)

The utility of ChatGPT in subspecialty consultation for patients (pts) with metastatic genitourinary (GU) cancer

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.227-227

2024

Volltextzugriff (PDF)

Comparative effectiveness of ChatGPT 4.0 and medical oncologists in telemedicine-based management of metastatic prostate carcinoma (mPC)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.226-226

2024

Volltextzugriff (PDF)

PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177 Lu-PSMA treatment

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.157-157

2024

Volltextzugriff (PDF)

Talazoparib for the treatment of prostate cancer

Expert opinion on pharmacotherapy, 2024-09, Vol.25 (13), p.1717-1727

2024

Volltextzugriff (PDF)

Anticoagulation for Splanchnic Vein Thrombosis in Patients with Myeloproliferative Neoplasms: A Systematic Review and Meta-Analysis

Blood, 2023-11, Vol.142 (Supplement 1), p.1817-1817

2023

Volltextzugriff (PDF)

Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi + Nivo) versus immune checkpoint inhibitors + tyrosine kinase inhibitors (ICI + TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4557-4557

2024

Volltextzugriff (PDF)

Changes in treatment (Rx) patterns and attrition rates in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4527-4527

2024

Volltextzugriff (PDF)

Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.70-70

2024

Volltextzugriff (PDF)

Disparities in the incidence of next-generation sequencing (NGS) among patients (pts) with advanced or metastatic prostate cancer (mPC) and urothelial carcinoma (mUC)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.542-542

2024

Volltextzugriff (PDF)

Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.188-188

2024

Volltextzugriff (PDF)

A Systematic Review of Crohn’s Disease Case Definitions in Administrative or Claims Databases

Inflammatory bowel diseases, 2023-05, Vol.29 (5), p.705-715

2023

Volltextzugriff (PDF)

Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor

Cancer, 2024-08, Vol.130 (15), p.2621-2628

2024

Volltextzugriff (PDF)

Anticoagulation for splanchnic vein thrombosis in myeloproliferative neoplasms: a systematic review and meta-analysis

Journal of thrombosis and haemostasis, 2024-08

2024

Volltextzugriff (PDF)

Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.547-547

2024

Volltextzugriff (PDF)

Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting

The Prostate, 2024-06, Vol.84 (9), p.888-892

2024

Volltextzugriff (PDF)

Abstract 2560: Genomic biomarkers of survival in patients (pts) with metastatic castrate-sensitive prostate cancer (mCSPC) undergoing androgen deprivation therapy (ADT) intensification (ADTi)

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.2560-2560

2024

Volltextzugriff (PDF)

Editorial Comment

Urology Practice, 2024-01, Vol.11 (1), p.161-161

2024

Volltextzugriff (PDF)

Abstract 1136: Tumor genomic and transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus do not achieve an optimal PSA response to androgen deprivation therapy intensification (ADTi)

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1136-1136

2024

Volltextzugriff (PDF)

Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers

JAMA network open, 2024-07, Vol.7 (7), p.e2423186

2024

Volltextzugriff (PDF)

Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US

JAMA network open, 2024-05, Vol.7 (5), p.e249417-e249417

2024

Volltextzugriff (PDF)

Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations

Kidney cancer, 2024-09, Vol.8 (1), p.135-142

2024

Volltextzugriff (PDF)

Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial

JAMA network open, 2024-07, Vol.7 (7), p.e2419966

2024

Volltextzugriff (PDF)

Trends and Disparities in Next-Generation Sequencing (NGS) Tumor Testing in Patients with Metastatic Prostate Cancer (mPC)

International Journal of Cancer Care and Delivery, 2024-10

2024

Volltextzugriff (PDF)

Clinical and Genomic Landscape of Neuroendocrine Prostate Cancer (NEC) vs. Prostate Adenocarcinoma (AdenoK)

International Journal of Cancer Care and Delivery, 2024-10

2024

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(9)
Science & Technology
(9)
Humans
(5)
Male
(4)
Aged
(3)
General & Internal Medicine
(3)
Medicine, General & Internal
(3)
Metastases
(3)
Metastasis
(3)
Middle Aged
(3)
Oncology
(3)
Prostatic Neoplasms - Pathology
(3)
Aged, 80 And Over
(2)
Androgen Receptors
(2)
Androgens
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Castration
(2)
Clinical Trials
(2)
Female
(2)
Inhibitors
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(19)
Journals@Ovid Full Text
(16)
Single Journals
(13)
IngentaConnect Journals
(11)
Ingenta.com
(10)
MEDLINE
(5)
Wiley-Blackwell Journals
(4)
Wiley Online Library Full Collection 2018
(3)
Taylor & Francis Online
(1)
Oxford journals
(1)
Oxford Journals 2020 Medicine
(1)
SpringerLink Series
(1)
SAGE Journals
(1)
Taylor & Francis Journals
(1)
Taylor & Francis
(1)

10 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape

The utility of ChatGPT in subspecialty consultation for patients (pts) with metastatic genitourinary (GU) cancer

Comparative effectiveness of ChatGPT 4.0 and medical oncologists in telemedicine-based management of metastatic prostate carcinoma (mPC)

PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177 Lu-PSMA treatment

Talazoparib for the treatment of prostate cancer

Anticoagulation for Splanchnic Vein Thrombosis in Patients with Myeloproliferative Neoplasms: A Systematic Review and Meta-Analysis

Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi + Nivo) versus immune checkpoint inhibitors + tyrosine kinase inhibitors (ICI + TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC)

Changes in treatment (Rx) patterns and attrition rates in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)

Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix

Disparities in the incidence of next-generation sequencing (NGS) among patients (pts) with advanced or metastatic prostate cancer (mPC) and urothelial carcinoma (mUC)

Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial

A Systematic Review of Crohn’s Disease Case Definitions in Administrative or Claims Databases

Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor

Anticoagulation for splanchnic vein thrombosis in myeloproliferative neoplasms: a systematic review and meta-analysis

Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC)

Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting

Abstract 2560: Genomic biomarkers of survival in patients (pts) with metastatic castrate-sensitive prostate cancer (mCSPC) undergoing androgen deprivation therapy (ADT) intensification (ADTi)

Editorial Comment

Abstract 1136: Tumor genomic and transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus do not achieve an optimal PSA response to androgen deprivation therapy intensification (ADTi)

Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers

Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US

Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations

Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial

Trends and Disparities in Next-Generation Sequencing (NGS) Tumor Testing in Patients with Metastatic Prostate Cancer (mPC)

Clinical and Genomic Landscape of Neuroendocrine Prostate Cancer (NEC) vs. Prostate Adenocarcinoma (AdenoK)

Suchergebnisse filtern